Prilenia Therapeutics B.V.: Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study

The primary and key secondary endpoints did not reach statistical significance Beneficial effects were observed across several secondary and exploratory endpoints Both pre-specified

Related Keywords

Waltham ,Massachusetts ,United States ,Herzliya ,Tel Aviv ,Israel ,Netherlands ,Naarden ,Noord Holland ,Dennis Riedl ,Seanm Healey ,Kristina Coppola ,Michaelr Hayden ,Department Of Neurology At Massachusetts ,Linkedin ,Sv Health Investors ,Twitter ,Investment Fund ,Drug Administration ,Head Of Corporate Communications ,Merit Cudkowicz ,Massachusetts General Hospital ,Julieanne Dorn Professor ,Harvard Medical ,Massachusetts General ,Lou Gehrig ,Motor Neuron Disease ,Orphan Drug Designation ,Fast Track ,Sands Capital ,Sectoral Asset Management ,Amplitude Ventures ,Del Aguila ,Corporate Communications ,Prilenia ,Herapeutics ,Nnounces ,Topline ,Results ,Pridopidine ,Hase ,Study ,